Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

Table 1 Physical characterization of the nanoformulations

Sample	Size (d. nm)	Polydispersity index (PdI)	Zeta potential (mV)	Irinotecan encapsulation efficiency (%)^a	PIC conjugation efficiency (%)^b	Number of PIC per Nal
Nal	126.5 ± 3.5	0.08 ± 0.01	− 19.6 ± 0.7	N/A	N/A	N/A
PIC–Nal	142.5 ± 5.9	0.06 ± 0.01	− 13.6 ± 0.6	N/A	66.5 ± 2.3	39.9 ± 1.4
Nal–IRI	151.0 ± 11.7	0.08 ± 0.01	− 16.6 ± 0.4	38.8 ± 4.4	N/A	N/A
PIC–Nal–IRI	158.8 ± 15.6	0.09 ± 0.03	− 14.8 ± 0.3	23.7 ± 2.2	48.0 ± 2.7	32.6 ± 2.6

Nal nanoliposome, PIC–Nal photoimmunoconjugate-nanoliposome, Nal–IRI nanoliposomal irinotecan, PIC–Nal–IRI photoimmunoconjugate-nanoliposomal irinotecan
^aEncapsulation efficiency (%): The molar ratio of irinotecan within the liposome after purification to that added initially. ^bConjugation efficiency (%): The molar ratio of PIC conjugated onto the liposomal construct to that added initially

ISSN: 1477-3155